|
ÇÒ¾¾¾ð½áÄ¡ |
Senior CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
6³â¡è |
ä¿ë½Ã |
03.09 |
|
|
GE Healthcare |
Lead RA Specialist
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
6³â¡è |
ä¿ë½Ã |
04.19 |
|
|
·º½ÌÅÏÄÁ¼³Æà INC. |
ÀÇ·á±â±â ¿¬±¸°³¹ß ¸Å´ÏÀú ¸ðÁý
°æºÏ ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
6³â¡è |
ä¿ë½Ã |
05.14 |
|
|
(ÁÖ)µð¾ËÁª |
¿¬±¸¼Ò ½Ã½ºÅÛ°ËÁõÆÀ °æ·Â»ç¿ø ¸ðÁý
°æ±â ±¤¸í½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
6³â¡è |
ä¿ë½Ã |
08.21 |
|
|
ÆĹ̼¿(ÁÖ) |
ÆĹ̼¿(ÁÖ) [±âȹ°³¹ßÆÀ] ¾à°¡µîÀç¾÷¹« ´ã´çÀÚ ¸ðÁý
°æ±â ¼º³²½Ã Áß¿ø±¸ | Çз¹«°ü |
°³¹ß/RA/´ë°ü |
6³â¡è |
ä¿ë½Ã |
12.13 |
|
|
(ÁÖ)Ŭ·¡½Ã½º |
±³À°°³¹ßÆÀ °æ·ÂÁ÷ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
6³â¡è |
ä¿ë½Ã |
04.16 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Clinical Project Leader
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
07.31 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Clinical Project Leader
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
06.02 |
|
|
°Ô¸£º£ÄÚ¸®¾Æ |
Senior RA Specialist - ¿Ü±¹°è Á¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
07.05 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
05.18 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
[LSK Global PS] DM Manager (Global Study Dedicated DM)
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
STAT/DM |
5³â¡è |
ä¿ë½Ã |
04.22 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Clinical Project Leader
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
06.12 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
05.12 |
|
|
(ÁÖ)µå¸²º¸¿ì |
äÇ÷ Ç÷´ç±â¼¾¼ ȸ»ç °æ·ÂÁ÷ ¸ðÁý(¹Ú»ç±Þ,ÈÇÐ ÈÇаøÇÐÀü
´ë±¸ µ¿±¸ | ´ëÇпø(¹Ú»ç) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
11.15 |
|
|
¹ÙÀÌ¿À´Ï¾Æ |
ÀÚȸ»ç(½á³ªÁ¨Å׶óǻƽ½º) ¿Ã¸®°íÇÕ¼º Chemist ¸ðÁý
´ëÀü À¯¼º±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
12.15 |
|